FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
March 30, 2016 11:56 AM EDT
Acadia Pharma (NASDAQ: ACAD) is fading early gains after an FDA panel backed the company's Nuplazid.
Worries about a potential Black Box Warning could be to blame.
Shares are up 9.8% after opening up 20%.
...
More
March 30, 2016 10:44 AM EDT
Aegis Capital affirms Acadia Pharma (Nasdaq: ACAD) with a Buy rating and $54 price target following a positive FDA panel review of Acadia's Nuplazid on Tuesday.
Analyst Robert LeBoyer sees post-approval studies for Nuplazid, commenting, Following the results of the Phase III trial in 2013, Acadia met with the FDA and was encouraged to file based only on that trial. Its strong results... More
March 30, 2016 6:49 AM EDT
Needham & Company reiterated a Buy rating and $49.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following a vote by the FDA Psychopharmacologic Drugs Advisory Committee in favor of Nuplazid approval for treatment of Parkinson's Disease Psychosis. Committee members generally viewed Nuplazid as effective, with a few... More
March 30, 2016 6:26 AM EDT
Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $44.00 (from $39.00) after an FDA panel voted positively on three questions regarding efficacy, and safety.
"Given the clear numerical results, and opinions voiced during... More
March 29, 2016 5:52 PM EDT
Acadia Pharma (NASDAQ: ACAD) is trading up 25.6% as trading resume following FDA panel backing for NUPLAZID.
...
More
March 29, 2016 5:43 PM EDT
Acadia Pharma (NASDAQ: ACAD) Resumes Trading at 5:45 PM ET
...
More
